Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence

Atherosclerosis is a long-term chronic inflammatory disease associated with increased concentrations of inflammatory hepatic markers, such as CRP and fibrinogen, and of peripheral origin, such as tumor necrosis factor (TNF)-&agr; and interleukin (IL)-6. Peroxisome proliferator-activated receptor (PPAR-)-&agr; is a ligand-activated transcription factor that regulates expression of key genes involved in lipid homeostasis and modulates the inflammatory response both in the vascular wall and the liver. PPAR-&agr; is activated by natural ligands, such as fatty acids, as well as the lipid-lowering fibrates. PPAR-&agr; agonists impact on different steps of atherogenesis: (1) early markers of atherosclerosis, such as vascular wall reactivity, are improved, (2) however, reduced expression of adhesion molecules on the surface of endothelial cells, accompanied by decreased levels of inflammatory cytokines, such as TNF-&agr;, IL-1, and IL-6, leads to a decreased leukocyte recruitment into the arterial wall; (3) in later stages of the atherosclerotic process, PPAR-&agr; agonists may promote plaque stabilization and reduce cardiovascular events, via effects on metalloproteinases, such as MMP9. Moreover, PPAR-&agr; activation by fibrates also impairs proinflammatory cytokine-signaling pathways in the liver resulting in the modulation of the acute phase response reaction via mechanisms independent of changes in lipoprotein levels. Effective coronary artery disease (CAD) prevention requires the use of agents that act beyond low-density lipoprotein cholesterol-lowering. PPAR-&agr; agonists appear to comprehensively address some of the abnormalities of the most common clinical phenotypes of the high CAD risk patient of the 21st century such as in the metabolic syndrome and type 2 diabetes: low high-density lipoprotein cholesterol, high triglycerides, small, dense low-density lipoprotein, and a proinflammatory, procoagulant state.

[1]  J. Beaumont,et al.  Peroxisome proliferator-activated receptor alpha and hypertensive heart disease. , 2004, Drugs.

[2]  Paul T. Williams,et al.  Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[3]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[4]  F. Hamada,et al.  Inhibition of Cytokine-induced Matrix Metalloproteinase 9 Expression by Peroxisome Proliferator-activated Receptor α Agonists Is Indirect and Due to a NO-mediated Reduction of mRNA Stability* , 2002, The Journal of Biological Chemistry.

[5]  M. Manns,et al.  Mediators of inflammation and acute phase response in the liver. , 2001, Cellular and molecular biology.

[6]  T. Willson,et al.  Peroxisome proliferator activated receptor agonists. , 1997, EXS.

[7]  T. Kordula,et al.  The role of Stat and C/EBP transcription factors in the synergistic activation of rat serine protease inhibitor-3 gene by interleukin-6 and dexamethasone. , 1996, The Biochemical journal.

[8]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[9]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[10]  E. Schiffrin,et al.  Effect of Peroxisome Proliferator–Activated Receptor-&agr; and -&ggr; Activators on Vascular Remodeling in Endothelin-Dependent Hypertension , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[11]  L. Lind.  Circulating markers of inflammation and atherosclerosis. , 2003, Atherosclerosis.

[12]  Roger A. Davis,et al.  Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ , 2004 .

[13]  J. Hendriks,et al.  Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[14]  E. Vellenga,et al.  c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). , 2001, Cytokine.

[15]  A. Hamsten,et al.  Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[16]  E. Schiffrin.  Peroxisome proliferator-activated receptors and cardiovascular remodeling. , 2005, American journal of physiology. Heart and circulatory physiology.

[17]  J. Després,et al.  Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Rothenbacher,et al.  Role of novel markers of inflammation in patients with stable coronary heart disease. , 2001, The American journal of cardiology.

[19]  C. Semenkovich,et al.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. , 2001, The Journal of clinical investigation.

[20]  P. Libby,et al.  PPARalpha activators inhibit tissue factor expression and activity in human monocytes. , 2001, Circulation.

[21]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[22]  D. Mikhailidis,et al.  Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels , 2002, Angiology.

[23]  T. Miki,et al.  NFkappaB regulates plasma apolipoprotein A-I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor alpha. , 2003, The Journal of biological chemistry.

[24]  J. Hradec,et al.  Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). , 2001, Cardiovascular research.

[25]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[26]  L. Madsen,et al.  PPARa activators improve insulin sensitivity and reduce adiposity , 2000 .

[27]  W. Hsueh,et al.  Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[28]  C. Zhang,et al.  Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[29]  B. Staels,et al.  Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. , 2000, FEBS letters.

[30]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[31]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[32]  J. Dhainaut,et al.  Hepatic response to sepsis: Interaction between coagulation and inflammatory processes , 2001, Critical care medicine.

[33]  E. Chaput,et al.  Fenofibrate protects lipoproteins from lipid peroxidation: Synergistic interaction with α-tocopherol , 1999, Lipids.

[34]  H. Baumann,et al.  Role of CAAT-enhancer binding protein isoforms in the cytokine regulation of acute-phase plasma protein genes. , 1992, The Journal of biological chemistry.

[35]  D. Kelly,et al.  A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  K. Huber,et al.  Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. , 2001, Thrombosis research.

[37]  T. Anderson,et al.  Assessment and treatment of endothelial dysfunction in humans. , 1999, Journal of the American College of Cardiology.

[38]  J. Després,et al.  Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients , 2003, Annals of medicine.

[39]  S. Kiechl,et al.  Metabolic Syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study , 2003, International Journal of Obesity.

[40]  B. Staels,et al.  Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. , 2000, The Journal of biological chemistry.

[41]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[42]  Bruno Derudas,et al.  Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.

[43]  Y. Chao,et al.  Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice* , 2002, The Journal of Biological Chemistry.

[44]  V. Laudet,et al.  Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. , 1999, Molecular endocrinology.

[45]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.

[46]  P. Libby.  Molecular bases of the acute coronary syndromes. , 1995, Circulation.

[47]  W. Bao,et al.  Activation of Peroxisome Proliferator–Activated Receptor-&agr; Protects the Heart From Ischemia/Reperfusion Injury , 2003, Circulation.

[48]  B. Staels,et al.  Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner , 2000 .

[49]  N. H. Nguyen,et al.  Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. , 2000, Journal of cardiovascular pharmacology.

[50]  A. Onat,et al.  Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. , 2002, Atherosclerosis.

[51]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[52]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[53]  J. Ward,et al.  Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor α , 2004, Cancer Research.

[54]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[55]  D. Playford,et al.  Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. , 2002, The American journal of cardiology.

[56]  J. Berger,et al.  Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 Cells , 2000 .

[57]  R. Westendorp,et al.  Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. , 2002, The American journal of medicine.

[58]  J. Huttunen,et al.  The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐up , 1994, Journal of internal medicine.

[59]  BartStaels,et al.  PPARα, but not PPARγ, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia , 2005 .

[60]  D. Playford,et al.  Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. , 2003, Atherosclerosis.

[61]  M. Freeman,et al.  Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia , 2005 .

[62]  G. Franceschini,et al.  Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[63]  G. Schonfeld,et al.  The effects of fibrates on lipoprotein and hemostatic coronary risk factors. , 1994, Atherosclerosis.

[64]  S. Jackson,et al.  Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. , 2000, Circulation.

[65]  B. Jude,et al.  PPARα Agonists Inhibit Tissue Factor Expression in Human Monocytes and Macrophages , 2001 .

[66]  C. Sirtori,et al.  Influences of lipid-modifying agents on hemostasis , 1993, Cardiovascular Drugs and Therapy.

[67]  B. Staels,et al.  Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.

[68]  J. Imig,et al.  Peroxisome Proliferator-Activated Receptor-&agr; Activation Reduces Salt-Dependent Hypertension During Chronic Endothelin B Receptor Blockade , 2005, Hypertension.

[69]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[70]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[71]  W. Wahli,et al.  Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.

[72]  A. Hamsten,et al.  Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.

[73]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[74]  H. Superko,et al.  Beyond LDL cholesterol reduction. , 1996, Circulation.

[75]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[76]  Kathleen M. Weil,et al.  Short-Term Triglyceride Lowering With Fenofibrate Improves Vasodilator Function in Subjects With Hypertriglyceridemia , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[77]  P. Libby,et al.  PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells , 1999 .

[78]  M. Taskinen,et al.  Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease: The Diabetes Atherosclerosis Intervention Study (DAIS) , 2003, Circulation.

[79]  K. Anderson,et al.  Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. , 1992, Journal of the American College of Cardiology.

[80]  B. Staels,et al.  Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators , 2000, Clinical chemistry and laboratory medicine.

[81]  Robert Kleemann,et al.  Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate* , 2004, Journal of Biological Chemistry.

[82]  Robert Kleemann,et al.  Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C/EBP-β complex formation , 2003 .

[83]  J. Keul,et al.  Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[84]  W. Wahli,et al.  The PPARalpha-leukotriene B4 pathway to inflammation control. , 1996, Nature.

[85]  T. Miki,et al.  NFκB Regulates Plasma Apolipoprotein A-I and High Density Lipoprotein Cholesterol through Inhibition of Peroxisome Proliferator-activated Receptor α* , 2003, Journal of Biological Chemistry.

[86]  T. Awata,et al.  The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells , 2001 .

[87]  B. Staels,et al.  Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[88]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[89]  K. Parhofer,et al.  Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[90]  B. Balkau,et al.  A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. , 2002, Atherosclerosis.

[91]  B. Okopień,et al.  Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. , 2003, International journal of clinical pharmacology and therapeutics.

[92]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[93]  M. Herregods,et al.  Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-&agr; and Peroxisome Proliferator–Activated Receptor-&ggr; Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice , 2004, Circulation.

[94]  B. Sobel,et al.  Direct Effects of Gemfibrozil on the Fibrinolytic System: Diminution of Synthesis of Plasminogen Activator Inhibitor Type 1 , 1992, Circulation.

[95]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[96]  Xianlin Han,et al.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. , 2002, The Journal of clinical investigation.

[97]  Tzung-Dau Wang,et al.  Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. , 2003, Atherosclerosis.

[98]  B Staels,et al.  Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. , 2001, The Journal of biological chemistry.

[99]  G. Pacini,et al.  Gemfibrozil improves insulin sensitivity and flow‐mediated vasodilatation in type 2 diabetic patients , 2001, European journal of clinical investigation.

[100]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[101]  Diabetes Atherosclerosis Intervention Study Investigators.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.

[102]  S. Verma,et al.  Endothelial function testing as a biomarker of vascular disease. , 2003, Circulation.

[103]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[104]  A. Zauberman,et al.  Smad Proteins Suppress CCAAT/Enhancer-binding Protein (C/EBP) β- and STAT3-mediated Transcriptional Activation of the Haptoglobin Promoter* , 2001, The Journal of Biological Chemistry.

[105]  M. Nieminen,et al.  Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.

[106]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[107]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[108]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. , 1998, Nature.

[109]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[110]  Robert Kleemann,et al.  Negative Regulation of Human Fibrinogen Gene Expression by Peroxisome Proliferator-activated Receptor α Agonists via Inhibition of CCAAT Box/Enhancer-binding Protein β* , 2001, The Journal of Biological Chemistry.

[111]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[112]  J. Després,et al.  A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. , 2002, Atherosclerosis.

[113]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[114]  S. Desiderio,et al.  Synergistic Activity of STAT3 and c-Jun at a Specific Array of DNA Elements in the α2-Macroglobulin Promoter* , 2001, The Journal of Biological Chemistry.

[115]  I. Simpson,et al.  Effect of Ciprofibrate on Platelet Aggregation and Fibrinolysis in Patients with Hypercholesterolaemia , 1985, Thrombosis and Haemostasis.

[116]  Robert Kleemann,et al.  Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. , 2004, Blood.

[117]  B. Okopień,et al.  Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. , 1998, International journal of clinical pharmacology and therapeutics.

[118]  W. Wahli,et al.  Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. , 1999, The Journal of clinical investigation.

[119]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.